

ASX RELEASE

Volpara Quarterly Results and Investor Conference Call

Wellington, NZ, 22 January 2019: <u>Volpara Health Technologies</u> ("Volpara"; ASX: VHT), a medical technology company whose AI imaging algorithms assist the early detection of breast cancer, is pleased to advise it will release its Appendix 4C – Quarterly Cash Flow Statement for the period ended 31 December 2018 (Q3 FY19) on 29 January 2019.

Investors are invited to join a conference call hosted by CEO Dr Ralph Highnam, CFO Craig Hadfield and CCO Mark Koeniguer at 9:30am AEST (11:30am NZST) 29 January 2019.

To pre-register, please follow this link:

https://services.choruscall.com.au/diamondpass/volpara-986652-invite.html

You will receive a calendar notification with dial-in details and a PIN for fast-track access to the call.

ENDS.

For further information, please contact:

Ralph Highnam, CEO Volpara Health Technologies ralph.highnam@volparasolutions.com t: +64 21 149 0541 Scott Newstead WE Buchan snewstead@we-buchan.com t: +61 3 9866 4722

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical applications for screening clinics provide feedback on breast density, compression, dose and quality, while its enterprise-wide software, VolparaEnterprise, provides role specific dashboards and wide-ranging benchmarking analytics to help clinics manage their business more efficiently.

VHT's technology and services have been used by customers and/or research projects in 36 countries and are supported by numerous patents, trademarks and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$40 million, including A\$20 million in April and May 2018. VHT is based in Wellington, New Zealand.

For more information visit www.volparasolutions.com

VHT uses the following definitions:

Total Contract Value (TCV): The value of contracts signed in the specified period. The revenue from these deals might be recognised over one or many years, and the customer might or might not have a cancellation clause of some kind.

Annual Recurring Revenue (ARR): The normalized amount of cash reasonably expected to be booked for the next 12 months based on the contracts signed previously, and assuming installation upon order.

Churn: The percentage of revenue from customers that either discontinue or reduce their subscription in a given 12-month period.